stockrow
Friday 6 November 2026
Export COCH’s income statement to Excel — free account
Envoy Medical, Inc.
COCH Healthcare Medical Devices
Envoy Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $241,000.00, up 7.11% from fiscal 2024.
- Revenue
- +57.1%
- EPS
- −42.9%
- Free cash flow
- −22.4%
Quarter to September 2026, against a year earlier
7.19
0.09
+1.27%
Follow COCH
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
306.71 | 398.06 | 195.91 | 63.80 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(12.99) | (15.10) | (7.56) | (2.70) | |
P/B ratio |
0.00 | 24.95 | 4.51 | 0.00 | |
Price to Tangible BV |
0.00 | 24.95 | 4.51 | 0.00 | |
EV/Sales |
376.20 | 450.93 | 218.86 | 175.34 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.04) | (4.33) | (2.49) | (2.32) | |
EV/FCF |
(4.00) | (4.30) | (2.47) | (2.30) | |
Quick Ratio |
1.03 | 1.56 | 2.07 | 0.33 | |
Current Ratio |
0.00 | 1.73 | 2.27 | 0.54 | |
Net Debt/EBITDA |
0.00 | 3.74 | 4.46 | 0.62 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.02 | 0.01 | 0.01 | 0.02 | |
Operating CF/Net income |
0.00 | 0.75 | 1.06 | 0.73 | |
Capex/Depreciation |
— | (0.02) | 0.00 | (0.56) | |
Research and Development Expense of Revenue |
4,662.12% | 6,141.18% | 9,338.46% | 6,070.67% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 4,333.33% | 5,238.46% | 2,261.33% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 482.35% | 725.64% | 153.33% | |
Graham Net Nets |
0.02 | 0.02 | 0.18 | (0.94) | |
Graham Number |
0.00 | 0.00 | 0.00 | 11.98 | |
Earnings Yield |
(13.36%) | (9.60%) | (15.19%) | (18.46%) | |
Free Cash Flow Yield |
(30.64%) | (26.35%) | (45.19%) | (119.55%) | |
Revenue per Share |
0.00 | 0.00 | 0.01 | 0.03 | |
Operating CF per Share |
— | (0.52) | (0.88) | (2.44) | |
Capex per Share |
— | 0.00 | 0.00 | (0.07) | |
Free Cash Flow per Share |
— | (0.52) | (0.88) | (2.52) | |
Cash per Share |
0.00 | 1.89 | 3.66 | 1.61 | |
Shareholders Equity per Share |
0.00 | 0.32 | 1.47 | (5.23) | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.32 | 1.47 | (5.23) | |
Free Cash Flow |
— | (5.46) | (6.06) | (5.86) | |
Working Capital |
(14.27) | 9.28 | 15.47 | (5.28) | |
Capital Expenditures |
— | (0.01) | — | (0.17) | |
Net Current Asset Value |
(20.69) | 1.27 | 8.02 | (14.44) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.12 | 0.00 | 2.29 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.06 | 0.06 | 0.06 | 0.44 | |
Average Payables |
2.13 | 1.83 | 1.68 | 2.29 | |
Average Inventory |
1.57 | 1.58 | 1.57 | 1.63 | |
Average Assets |
13.67 | 16.92 | 20.10 | 10.05 | |
Average Common Equity |
(4.60) | (13.28) | (7.03) | (15.50) |
Columns are period end dates · fundamentals updated 5 Nov 2026